Author details

Full Name

Krisha McKee

Affiliation

ORCID

Career Start Year

2010

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37098956	Diverse Murine Vaccinations Reveal Distinct Antibody Classes to Target Fusion Peptide and Variation in Peptide Length to Improve HIV Neutralization.		2023
37989731	Antibody-directed evolution reveals a mechanism for enhanced neutralization at the HIV-1 fusion peptide site.		2023
37345226	Improved pharmacokinetics of HIV-neutralizing VRC01-class antibodies achieved by reduction of net positive charge on variable domain.		2023
37436900	Improved HIV-1 neutralization breadth and potency of V2-apex antibodies by in silico design.		2023
36729903	Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency.	MAbs	2023
37349337	Trispecific antibody targeting HIV-1 and T cells activates and eliminates latently-infected cells in HIV/SHIV infections.	Nat Commun	2023
34986348	Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys.	Cell Rep	2022
36284200	Engineering of HIV-1 neutralizing antibody CAP256V2LS for manufacturability and improved half life.	Scientific Reports	2022
34328065	A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention.	mAbs	2021
34200826	Structures of HIV-1 Neutralizing Antibody 10E8 Delineate the Mechanistic Basis of Its Multi-Peak Behavior on Size-Exclusion Chromatography.	Antibodies (Basel)	2021
33121334	Removal of variable domain -linked glycosylation as a means to improve the homogeneity of HIV-1 broadly neutralizing antibodies.	mAbs	2020
32268107	Structure of Super-Potent Antibody CAP256-VRC26.25 in Complex with HIV-1 Envelope Reveals a Combined Mode of Trimer-Apex Recognition.	Cell Rep	2020
32690707	Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody.	Proc Natl Acad Sci U S A	2020
30876875	Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual.	Immunity	2019
31732167	Vaccination with Glycan-Modified HIV NFL Envelope Trimer-Liposomes Elicits Broadly Neutralizing Antibodies to Multiple Sites of Vulnerability.	Immunity	2019
30604750	Lattice engineering enables definition of molecular features allowing for potent small-molecule inhibition of HIV-1 entry.	Nature Communications	2019
30471922	Structural Survey of Broadly Neutralizing Antibodies Targeting the HIV-1 Env Trimer Delineates Epitope Categories and Characteristics of Recognition.	Structure	2019
29548671	A Neutralizing Antibody Recognizing Primarily N-Linked Glycan Targets the Silent Face of the HIV Envelope.	Immunity	2018
29867235	Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1.	Nat Med	2018
29902444	Interdomain Stabilization Impairs CD4 Binding and Improves Immunogenicity of the HIV-1 Envelope Trimer.		2018
29491415	Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity.	Nature Communications	2018
29451984	Two-Component Ferritin Nanoparticles for Multimerization of Diverse Trimeric Antigens.	ACS Infect Dis	2018
29444432	Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody.	Cell Rep	2018
29558468	Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors.	PLoS ONE	2018
29643249	Neutralizing Antibody Responses following Long-Term Vaccination with HIV-1 Env gp140 in Guinea Pigs.	Journal of Virology	2018
28052137	Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting.	PLoS Pathog	2017
28445724	Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation.	Cell Rep	2017
28931639	Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques.	Science	2017
28783671	Potent and broad HIV-neutralizing antibodies in memory B cells and plasma.	Science immunology	2017
28298420	Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodies.	Science Translational Medicine	2017
27654288	Multiple Antibody Lineages in One Donor Target the Glycan-V3 Supersite of the HIV-1 Envelope Glycoprotein and Display a Preference for Quaternary Binding.	J Virol	2016
27067056	Key gp120 Glycans Pose Roadblocks to the Rapid Development of VRC01-Class Antibodies in an HIV-1-Infected Chinese Donor.	Immunity	2016
27299673	Developmental Pathway of the MPER-Directed HIV-1-Neutralizing Antibody 10E8.	PLoS One	2016
26879974	HIV-1 Vaccine-elicited Antibodies Reverted to Their Inferred Naive Germline Reveal Associations between Binding Affinity and in vivo Activation.	Scientific Reports	2016
27053554	Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design.	J Virol	2016
27174988	Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody.	Science	2016
27851912	Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth.	Immunity	2016
26446600	Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization.	Journal of Virology	2015
25800131	Eliminating antibody polyreactivity through addition of N-linked glycosylation.	Protein Science	2015
25865483	Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection.	Cell	2015
26004070	Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors.	Cell	2015
26468542	New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency.	J Virol	2015
25979984	Correction for Ingale et al., Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies.	Journal of Virology	2015
26530382	Rhesus Macaque B-Cell Responses to an HIV-1 Trimer Vaccine Revealed by Unbiased Longitudinal Repertoire Analysis.	mBio	2015
26023780	Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site.	PLoS Pathogens	2015
25253346	Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies.	Journal of Virology	2014
24391217	Antibodies VRC01 and 10E8 neutralize HIV-1 with high breadth and potency even with Ig-framework regions substantially reverted to germline.	J Immunol	2014
24335316	Structural basis for HIV-1 neutralization by 2F5-like antibodies m66 and m66.6.	Journal of Virology	2014
24590074	Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies.	Nature	2014
25245278	HIV-1 envelope glycoprotein trimer immunogenicity elicited in the presence of human CD4 alters the neutralization profile.	AIDS Research and Human Retroviruses	2014